Callan Capital Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P Dividend ETF
SDY
|
+$3.59M |
| 2 |
Invesco FTSE RAFI US 1000 ETF
PRF
|
+$3.12M |
| 3 |
Alerian MLP ETF
AMLP
|
+$2.15M |
| 4 |
Vanguard FTSE Europe ETF
VGK
|
+$2.11M |
| 5 |
PIMCO Active Bond Exchange-Traded Fund
BOND
|
+$1.07M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CAMP
CalAmp Corp.
CAMP
|
+$161K |
| 2 |
IMUC
ImmunoCellular Therapeutics, Ltd.
IMUC
|
+$57.4K |
| 3 |
EXK
Endeavour Silver
EXK
|
+$46K |
| 4 |
iShares MSCI Emerging Markets ETF
EEM
|
+$37.7K |
| 5 |
AXU
Alexco Resource Corp
AXU
|
+$14K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 98.39% |
| 2 | Healthcare | 1.58% |
| 3 | Materials | 0.04% |
| 4 | Technology | 0% |
Similar funds
Callan Capital's Q3 2013 Portfolio in Review
As of Q3 2013, Callan Capital held 55 positions worth $210M, up 20% from $175M the previous quarter. Its ten largest holdings account for 73% of the portfolio.
Callan Capital deployed $23.5M of net new capital in Q3 2013, opening 9 new positions and adding to 26 existing holdings. Its largest new stake was PIMCO Active Bond Exchange-Traded Fund: 10,189 shares worth $1.08M.
By sector, the portfolio is most concentrated in Miscellaneous at 98% of assets, down from 98% a quarter earlier, followed by Healthcare and Materials.
On the sell side, the largest reduction was ImmunoCellular Therapeutics, Ltd., an estimated $57.4K trimmed.
- Callan Capital's largest Q3 2013 buy was PIMCO Active Bond Exchange-Traded Fund: 10,189 shares worth $1.08M.
- Callan Capital added most to State Street SPDR S&P Dividend ETF in Q3 2013, an estimated $3.59M increase.
- Callan Capital's biggest Q3 2013 reduction was ImmunoCellular Therapeutics, Ltd., cutting an estimated $57.4K.
- Callan Capital fully exited CalAmp Corp. in Q3 2013, selling an estimated $161K.
- Callan Capital's ten largest holdings make up 73% of its $210M portfolio in Q3 2013.
- Callan Capital opened 9 new positions and closed 9 in Q3 2013.
- Callan Capital's portfolio value rose 20% quarter-over-quarter to $210M.
Based on Callan Capital's 13F filing for Q3 2013, filed 14 Nov 2013.